Prothena traded at $29.69 this Tuesday July 5th, increasing $1.80 or 6.45 percent since the previous trading session. Looking back, over the last four weeks, Prothena gained 13.32 percent. Over the last 12 months, its price fell by 46.71 percent. Looking ahead, we forecast Prothena to be priced at 26.81 by the end of this quarter and at 23.82 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
29.69
Daily Change
6.45%
Yearly
-46.71%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 15.27 0.90 6.26% -36.72%
Agios Pharmaceuticals 25.45 2.09 8.95% -55.55%
Akebia Therapeutics 0.41 0.02 5.14% -88.35%
ALKERMES 31.43 0.90 2.95% 22.97%
Alnylam Pharmaceuticals 150.73 2.48 1.67% -13.56%
Amgen 246.73 1.18 0.48% 1.26%
Biogen 212.58 1.95 0.93% -38.36%
Bluebird Bio 5.05 0.77 17.99% -83.73%
BioMarin Pharmaceutical 86.36 1.38 1.62% 2.12%
Exelixis 22.27 0.70 3.25% 21.10%
Intercept Pharmaceuticals 15.15 1.02 7.22% -20.43%
Incyte Corp 79.25 1.58 2.03% -4.91%
Ionis Pharmaceuticals 37.85 -0.21 -0.55% -3.76%
Intra Cellular Therapies 57.09 1.92 3.48% 35.61%
MacroGenics 3.31 0.26 8.52% -88.38%
Neurocrine Biosciences 98.30 -0.95 -0.96% 0.87%
Nektar Therapeutics 3.93 0.18 4.80% -76.76%
Prothena 29.69 1.80 6.45% -46.71%
Ultragenyx Pharmaceutical 63.80 1.15 1.84% -30.21%
Regeneron Pharmaceuticals 596.56 1.16 0.19% 2.46%
Seattle Genetics 176.77 -3.34 -1.85% 15.91%
Vertex Pharmaceuticals 288.98 1.66 0.58% 45.22%
Immunic Inc. 3.77 0.30 8.65% -69.35%
Xoma 21.00 0.16 0.77% -38.25%

Indexes Price Day Year
USND 11322 194.39 1.75% -22.79%
US2000 1741 13.57 0.79% -23.44%

Prothena
Prothena Corporation PLC is a late-stage clinical company. The Company is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. It is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The Company's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The Company's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aß) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.